A panel at the annual American Heart Association conference held in Chicago, Illinois, discussed ways in which cardiovascular disease (CVD) care was affected by equity issues between White and Black patients.
A panel that took place during the American Heart Association Scientific Sessions, held November 5-7 in Chicago, Illinois, discussed how better blood pressure (BP) control was associated with lower cardiovascular disease (CVD) risk. An expert at the panel also found ways in which inequity in CVD care and BP control affected White and Black patients differently in CVD care.
Paul Muntner, PhD, gave a presentation on racial disparities in BP control and CVD. “Even after adjustments, what we see is that Black [people] are 32% more likely to die of [CVD],” he said to begin the presentation.
The racial disparity in BP control was found to have increased over time, according to Muntner. Research found that the difference in White vs Black people who had controlled BP (< 140/90 mm Hg) was 9.1 percentage points in 1999 to 2000. However, by 2017 to 2018, this difference had increased, with 66.4% of White participants having controlled BP compared with 51.7% of Black participants.
Muntner also presented data that found that the percentage of Black Americans who had hypertension and had BP control decreased from 2009 to 2020. Likewise, the percentage of Black Americans who took antihypertensive medication also decreased from 2009 to 2020 compared with White Americans, Hispanic Americans, and Asian Americans, whose levels remained similar through the same time period. Black Americans were also found to have a decreased awareness that they have hypertension.
“We see a decrease in blood pressure control. Along with that, we see some of the underlying damages of a decrease in awareness of hypertension [and] a decrease in antihypertensive medication use,” said Muntner.
Muntner went on to provide the results of a study under review for publication that evaluated social determinants of health (SDOH) and how it related to the percentage of people with uncontrolled BP. The study included 30,239 participants from all 50 states.
BP was measured twice during an at-home study visit and both measurements were averaged. Adverse SDOH that were included in this study were: having less than a high school education, having an annual household income of less than $35,000, residing in a disadvantaged neighborhood, not having health insurance, living in a health professional shortage area, and living in a high poverty zip code.
The study found that the percentage of people who had uncontrolled BP increased as the number of adverse SDOH increased. The percentage of people with uncontrolled BP with no SDOH was higher in Black Americans (25.4%) compared with White Americans (23.4%). The percentage of people with uncontrolled BP was also higher in Black Americans (40.2%) compared with White Americans (33.2%) when the participants had 4 or more adverse SDOH.
Muntner also presented data from the Jackson Heart Study. This study found that 76.4% of Black participants had controlled BP at baseline, of which 48.9% maintained it after 8 years. The Black participants who maintained BP control had a decreased risk of CVD events compared with the participants who had uncontrolled BP.
“Consistent blood pressure can be achieved and it does have benefits for cardiovascular risk reduction,” said Muntner.
BP equity could also reduce the amount of CVD events per 10 years, according to data of an in progress study presented by Muntner. It was found that 250,000 CVD events that occur through 10 years could be avoided if BP equity was achieved between Black Americans and White Americans.
Muntner concluded that the differences in BP control between Black and White Americans has increased, with SDOH making up a substantial proportion of the differences between the 2 groups. Maintaining BP control and earning BP equity in Black Americans should be the goal in the United States, as it can reduce the number of reduce CVD risk and CVD events respectively.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen